<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806168</url>
  </required_header>
  <id_info>
    <org_study_id>H12-01578</org_study_id>
    <secondary_id>V12-01578</secondary_id>
    <nct_id>NCT01806168</nct_id>
  </id_info>
  <brief_title>rTMS in the Treatment of PTSD</brief_title>
  <official_title>The Role of Fast or Slow Repetitive Transcranial Magnetic Stimulation as Adjunct Therapy in Civilian Post-Traumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vancouver Coastal Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of repetitive transcranial magnetic
      stimulation (rTMS) in civilian patients with a confirmed diagnosis of post-traumatic stress
      disorder (PTSD). This research study will determine whether low-frequency (1 Hertz [Hz]) or
      high-frequency (10 Hz) rTMS over the right dorsolateral prefrontal cortex (DLPFC) has an
      effect on symptoms of PTSD compared to sham rTMS treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician-Administered PTSD Scale for DSM-IV (CAPS)</measure>
    <time_frame>Change from baseline to endpoint (Week 2)</time_frame>
    <description>Clinician rated for Post traumatic Stress Disorder</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTSD Checklist for Civilians (PCL-C)</measure>
    <time_frame>Change from baseline to endpoint (Week 2)</time_frame>
    <description>The PCL is a standardized self-report rating scale for PTSD comprising 17 items that correspond to the key symptoms of PTSD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale, 21-item version (HAMD-21)</measure>
    <time_frame>Change from baseline to endpoint (Week 2)</time_frame>
    <description>Clinician rated for Depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology -- Self-Report (QIDS-SR)</measure>
    <time_frame>Change from baseline to endpoint (Week 2)</time_frame>
    <description>Self Report for Depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Inventory (BAI)</measure>
    <time_frame>Change from baseline to endpoint (Week 2)</time_frame>
    <description>Self Report for Anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generalized Anxiety Disorder (GAD-7) Scale</measure>
    <time_frame>Change from baseline to endpoint (Week 2)</time_frame>
    <description>Self Report for Anxiety</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Neuropsychological testing</measure>
    <time_frame>Change from baseline to endpoint (Week 2)</time_frame>
    <description>Cognitive tool</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Changer from baseline to endpoint (week 2)</time_frame>
    <description>Self report for Depression</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Post-traumatic Stress Disorder (PTSD)</condition>
  <arm_group>
    <arm_group_label>Low-frequency (1 Hz) rTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-frequency active stimulation over the right DLPFC on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-frequency (10 Hz) rTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-frequency active stimulation over the right DLPFC on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham stimulation over the right DLPFC on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rTMS</intervention_name>
    <description>Magstim Super Rapid-2</description>
    <arm_group_label>High-frequency (10 Hz) rTMS</arm_group_label>
    <arm_group_label>Low-frequency (1 Hz) rTMS</arm_group_label>
    <arm_group_label>Sham rTMS</arm_group_label>
    <other_name>repetitive transcranial magnetic stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary diagnosis of PTSD as determined by a structured interview using the Mini
             International Neuropsychiatric Interview (MINI)

          -  no change in psychotropic medications within 4 weeks before the start of rTMS

          -  age &gt; 19 years and &lt; 70 years

          -  competency to give informed consent

        Exclusion Criteria:

          -  any non-fixed metal object or implant (including cochlear implants) in brain, skull,
             scalp, or neck within 30 cm of the magnetic rTMS coil

          -  implantable devices, including cardiac pacemakers and defibrillators

          -  other contraindications to rTMS, including history of seizures (except childhood
             febrile seizures) or recent and unexplained syncope, first-degree relative with a
             history of epilepsy, treatment with a medication known to substantially decrease the
             seizure threshold, or pregnancy

          -  psychiatric diagnoses of psychosis or psychotic disorder (including psychotic
             depression), bipolar type I disorder, or organic mental disorders

          -  substance abuse/dependence within the past 3 months

          -  active suicidal risk as judged by the clinician

          -  borderline or antisocial personality disorder

          -  acute medical illness, including cancer

          -  any significant central nervous system disorder, such as brain mass, stroke, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Ong, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vancouver Coastal Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 4, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <last_update_submitted>January 26, 2019</last_update_submitted>
  <last_update_submitted_qc>January 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Peter Y Chan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Post-traumatic stress disorder</keyword>
  <keyword>Repetitive transcranial magnetic stimulation</keyword>
  <keyword>Civilians</keyword>
  <keyword>Neurostimulation</keyword>
  <keyword>Dorsolateral prefrontal cortex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

